Shares Finnish group Faron Pharmaceuticals were trading down more than 80 percent on the London Stock Exchange after its key drug traumakine failed in acute respiratory distress syndrome (ARDS).
News
AstraZeneca sheds Seroquel rights
AstraZeneca has sold off certain rights to its antipsychotics Seroquel and Seroquel XR in certain territories – including the UK – to Luye Pharma.
Five therapies endorsed for use on NHS Scotland
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
NICE OKs three new therapies for blood cancer
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
First-line use of Roche’s Tecentriq given priority review
US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
Darzalex combo wins nod for newly diagnosed multiple myeloma
Janssen’s Darzalex has become the first monoclonal antibody to be approved in the US to treat patients newly diagnosed with multiple myeloma.
Herceptin biosimilar Herzuma launched in Europe
Mundipharma announced that its network of companies has kicked off the rollout of Celltrion’s Herceptin biosimilar Herzuma in Europe.
CHMP takes negative view on Sarepta’s DMD therapy
Sarepta has indicated a delay to getting its Duchenne muscular dystrophy therapy Exondys approved in Europe, revealing that the European Medicine Agency’s Committee for Medicinal Products for Human Use’s trend vote was negative.
Merck invests in Moderna
Merck is investing $125 million in Moderna under a new deal that expands the firms’ 2016 partnership to develop messenger RNA cancer vaccines.
Long-term benefit of Qarziba uncertain, says NICE
The National Institute for Health and Care Excellence has ruled against the provision of NHS funding for EUSA Pharma’s neuroblastoma treatment Qarziba.
Janssen acquires BeneVir Biopharm to advance immunotherapy regimens
BeneVir engineers oncolytic viruses tailored to infect and destroy cancer cells
Bayer cuts profit guidance
Business hit by strong Euro
Novartis’ biosimilar rituximab delayed in US
Rejection is another win for drugs’ originator Roche
Merck’s MS treatment shows promise in new data
HRA and HRA + DAT patients showed responses to Mavenclad that were generally better than previous outcomes in study population
CRUK launches £18m fund for brain tumour research
Brain Tumour Awards aim to help advance understanding about the biology of the disease and the challenges translating discoveries into treatments.
